Implantable cardioverter defibrillators in left ventricular assist device patients: Α systematic review and

Filippos-Paschalis Rorris1, Constantine N Antonopoulos1, Christos P Kyriakopoulos2

  • 1Department of Thoracic and Cardiovascular Surgery, Evangelismos General Hospital, Athens, Greece.

Insights

Implantable cardioverter-defibrillators (ICDs) do not impact overall mortality in continuous flow left ventricular assist device (CF-LVAD) patients. However, ICDs show a trend towards improved heart transplantation success and a survival benefit in European but not US patient groups.

Area of Science:

  • Cardiology
  • Medical Devices
  • Heart Failure Management

Background:

  • Implantable cardioverter-defibrillators (ICDs) are standard for preventing sudden cardiac death in heart failure.
  • Guidelines conflict on ICD use in patients with continuous flow left ventricular assist devices (CF-LVADs).

Purpose of the Study:

  • To evaluate the impact of ICDs on mortality and heart transplantation in CF-LVAD patients.
  • To compare outcomes between US and European studies regarding ICD use in CF-LVAD patients.

Main Methods:

  • Systematic review and meta-analysis adhering to PRISMA guidelines.
  • Inclusion of studies comparing ICD use in CF-LVAD patients.
  • Pooled odds ratios calculated for all-cause mortality and successful bridge to transplantation.

Main Results:

  • ICD use was not associated with all-cause mortality in CF-LVAD patients (OR: 0.85, 95% CI: 0.64-1.12).
  • A trend towards increased likelihood of successful bridge to transplantation was observed with ICDs (OR: 1.12, 95% CI: 1.0-1.3).
  • European studies showed decreased mortality with ICDs (OR: 0.58), while US studies showed increased mortality (OR: 1.2).

Conclusions:

  • Overall survival benefit of ICDs in CF-LVAD patients was not demonstrated.
  • Significant differences in outcomes and baseline characteristics exist between US and European CF-LVAD populations.
  • Further investigation into population-specific benefits of ICDs in CF-LVAD patients is warranted.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
83
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
107
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
60
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
68
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
186
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
92